These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 19176456

  • 1. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T, Pavan GM, Virdis E, Greco A, Fermeglia M, Sandri M, Pricl S, Pierotti MA, Pilotti S, Tamborini E.
    J Natl Cancer Inst; 2009 Feb 04; 101(3):194-204. PubMed ID: 19176456
    [Abstract] [Full Text] [Related]

  • 2. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR.
    Clin Cancer Res; 2007 Jan 01; 13(1):170-81. PubMed ID: 17200352
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Tarn C, Merkel E, Canutescu AA, Shen W, Skorobogatko Y, Heslin MJ, Eisenberg B, Birbe R, Patchefsky A, Dunbrack R, Arnoletti JP, von Mehren M, Godwin AK.
    Clin Cancer Res; 2005 May 15; 11(10):3668-77. PubMed ID: 15897563
    [Abstract] [Full Text] [Related]

  • 5. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S, Duensing A, Demetri GD, Fletcher JA.
    Oncogene; 2007 Nov 29; 26(54):7560-8. PubMed ID: 17546049
    [Abstract] [Full Text] [Related]

  • 6. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K, Naomoto Y, Gunduz M, Matsuoka J, Yamatsuji T, Shirakawa Y, Nobuhisa T, Okawa T, Takaoka M, Tomono Y, Hiroyuki O, Gunduz E, Tanaka N.
    Oncol Rep; 2005 Sep 29; 14(3):645-50. PubMed ID: 16077968
    [Abstract] [Full Text] [Related]

  • 7. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S, Pan YL, Tao DY, Wang JL, Huang KE.
    Scand J Gastroenterol; 2009 Sep 29; 44(6):760-3. PubMed ID: 19096980
    [Abstract] [Full Text] [Related]

  • 8. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S.
    Clin Cancer Res; 2007 Apr 15; 13(8):2369-77. PubMed ID: 17438095
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus HU.
    Verh Dtsch Ges Pathol; 2007 Apr 15; 91():165-8. PubMed ID: 18314611
    [Abstract] [Full Text] [Related]

  • 12. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
    Tamborini E, Gabanti E, Lagonigro MS, Negri T, Pilotti S, Pierotti MA, Pricl S.
    Cancer Res; 2005 Feb 01; 65(3):1115; author reply 1115. PubMed ID: 15705916
    [No Abstract] [Full Text] [Related]

  • 13. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M.
    ChemMedChem; 2009 Jan 01; 4(1):118-26. PubMed ID: 19039816
    [Abstract] [Full Text] [Related]

  • 14. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K, Matsumoto T, Hirota S.
    Gan To Kagaku Ryoho; 2009 Jul 01; 36(7):1080-5. PubMed ID: 19620796
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
    Bertucci F, Goncalves A, Monges G, Madroszyk A, Guiramand J, Moutardier V, Noguchi T, Dubreuil P, Sobol H.
    Oncol Rep; 2006 Jul 01; 16(1):97-101. PubMed ID: 16786129
    [Abstract] [Full Text] [Related]

  • 17. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, Füzesi L.
    Ann Surg Oncol; 2007 Feb 01; 14(2):526-32. PubMed ID: 17139461
    [Abstract] [Full Text] [Related]

  • 18. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA.
    Oncogene; 2007 Sep 27; 26(44):6386-95. PubMed ID: 17452978
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.